← BACK TO NEWS
SOM Biotech announces the presentation of the Phase2b study results
SOM Biotech presents the Phase 2b study results with SOM3355 demonstrating a unique profile with robust improvements of chorea in Huntington’s Disease Patients and a safe profile with no somnolence, no akathisia and no impact on depression, suicidality or cognition.